| Exec date | Filing date | Company | Role | Signal | Confidence | Shares | % of shares | Under plan? | Amount (USD) |
|---|---|---|---|---|---|---|---|---|---|
| Jun 2, 2025 | Jun 3, 2025 | AN2 Therapeutics, Inc. | CEO | Buy | 68.8 | +10,000 | 0.66% | ✗ | $10.7K |
| Nov 18, 2024 | Nov 18, 2024 | AN2 Therapeutics, Inc. | CEO | Buy | 83.8 | +50,000 | 4.48% | ✗ | $50K |
| Jan 2, 2024 | Jan 4, 2024 | AN2 Therapeutics, Inc. | CEO | Sell | 50.0 | -2,777 | -0.23% | ✓ | $55.8K |
| May 15, 2023 | May 15, 2023 | AN2 Therapeutics, Inc. | CEO | Buy | 72.5 | +10,000 | 0.99% | ✗ | $53.8K |
| Nov 10, 2022 | Nov 14, 2022 | AN2 Therapeutics, Inc. | CEO | Sell | 10.0 | -4,436 | -47.48% | ✓ | $68K |
| Nov 8, 2022 | Nov 9, 2022 | AN2 Therapeutics, Inc. | CEO | Sell | 7.5 | -17,166 | -77.77% | ✓ | $267.8K |
| Nov 3, 2022 | Nov 7, 2022 | AN2 Therapeutics, Inc. | CEO | Sell | 7.5 | -35,196 | -87.76% | ✓ | $558.3K |
| Oct 31, 2022 | Nov 2, 2022 | AN2 Therapeutics, Inc. | CEO | Sell | 10.0 | -4,232 | -46.31% | ✓ | $64.6K |
| Oct 27, 2022 | Oct 28, 2022 | AN2 Therapeutics, Inc. | CEO | Sell | 13.8 | -2,607 | -34.70% | ✓ | $39.6K |
| Oct 24, 2022 | Oct 26, 2022 | AN2 Therapeutics, Inc. | CEO | Sell | 10.0 | -9,350 | -65.58% | ✓ | $147.4K |
| Oct 20, 2022 | Oct 24, 2022 | AN2 Therapeutics, Inc. | CEO | Sell | 7.5 | -21,244 | -81.24% | ✓ | $349.9K |